European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer

ESMO Open

Volumn 2, Issue 2, 2017, Pages

  Stanel, Stefan Cristian ^a   Sjöberg, Jan ^b   Salmonson, Tomas ^b   Foggi, Paolo ^c   Caleno, Mariapaola ^c   Melchiorri, Daniela ^d   Gravanis, Iordanis ^a   Tzogani, Kyriaki ^a   Pignatti, Francesco ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b MEDICAL PRODUCTS AGENCY   (Sweden)

^c ITALIAN MEDICINES AGENCY   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aflibercept; Approval; EMA; European Medicines Agency; Metastatic Colorectal Cancer; Zaltrap

Indexed keywords

EID: 85045419466     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000190     Document Type: Review

References (16)

1. Van Cutsem E, Cervantes A, Nordlinger B, et al. ESMO Guidelines Working Group. Metastatic colorectal Cancer: esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(Suppl 3):iii1-9.
2. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal Cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
3. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
5. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal Cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 2007;25:1539-44.
6. Wilke H, Glynne-Jones R, Thaler J, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal Cancer progressing on irinotecan: mabel study. J Clin Oncol 2008;26:5335-43.
7. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal Cancer. N Engl J Med 2004;351:337-45.
8. Peeters M, Price TJ, Cervantes A, et al. Randomized phase III study of Panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal Cancer. J Clin Oncol 2010;28:4706-13.
9. Grothey A, Van Cutsem E, Sobrero A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal Cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
10. Rudge JS, Holash J, Hylton D, et al. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-70.
11. Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal Cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506.
12. Bennouna J, Sastre J, Arnold D, et al. ML18147 Study Investigators. Continuation of Bevacizumab after first progression in metastatic colorectal Cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37.
13. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26:5326-34.
14. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and Bevacizumab for metastatic colorectal Cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-9.
15. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer 2010;9:274-81.
16. Folprecht G, Pericay C, Saunders MP, et al. Oxaliplatin and 5-FU/ folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study. Ann Oncol 2016;27:1273-9.